98 related articles for article (PubMed ID: 21574147)
1. [Prostate I-125 brachytherapy: critical evaluation of mid-term oncologic and functional results in 250 cases].
Gastaldi E; Chiono L; Gallo F; Giberti C
Urologia; 2011; 78(2):86-91. PubMed ID: 21574147
[TBL] [Abstract][Full Text] [Related]
2. [Prostate brachytherapy: oncological and functional results after 400 cases].
Gastaldi E; Chiono L; Gallo F; Giberti C
Urologia; 2014; 81 Suppl 23():S15-9. PubMed ID: 24665030
[TBL] [Abstract][Full Text] [Related]
3. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years.
Stone NN; Stock RG
Urology; 2007 Feb; 69(2):338-42. PubMed ID: 17320674
[TBL] [Abstract][Full Text] [Related]
4. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
5. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
6. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
Borchers H; Kirschner-Hermanns R; Brehmer B; Tietze L; Reineke T; Pinkawa M; Eble MJ; Jakse G
BJU Int; 2004 Oct; 94(6):805-11. PubMed ID: 15476513
[TBL] [Abstract][Full Text] [Related]
7. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
[TBL] [Abstract][Full Text] [Related]
8. Salvage low-dose-rate brachytherapy for prostate cancer local recurrence after radical prostatectomy: our first three patients.
Gastaldi E; Gallo F; Chiono L; Giberti C
Urologia; 2014; 81(1):46-50. PubMed ID: 24474541
[TBL] [Abstract][Full Text] [Related]
9. Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up.
Ferrer M; Guedea F; Suárez JF; de Paula B; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Boladeras A; Ayala A; Craven-Bratle J; Ávila M; Cunillera O; Pardo Y; Alonso J; Aguiló F;
Radiother Oncol; 2013 Aug; 108(2):306-13. PubMed ID: 23849168
[TBL] [Abstract][Full Text] [Related]
10. Dosimetry doesn't seem to predict the control of organ-confined prostate cancer after I-125 brachytherapy. Evaluation in 150 patients.
Gastaldi E; Chiono L; Gallo F; Schenone M; Ninotta G; Chiarlone R; Ghiso G; Giberti C
Arch Ital Urol Androl; 2009 Dec; 81(4):215-7. PubMed ID: 20608144
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
12. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
13. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy.
Solan AN; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1468-74. PubMed ID: 18922652
[TBL] [Abstract][Full Text] [Related]
14. Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Longterm results.
Prada PJ; Anchuelo J; Blanco AG; Paya G; Cardenal J; Acuna E; Ferri M; Vazquez A; Pacheco M; Sanchez J
Int Braz J Urol; 2016; 42(1):47-52. PubMed ID: 27136466
[TBL] [Abstract][Full Text] [Related]
15. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
[TBL] [Abstract][Full Text] [Related]
16. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
Aluwini S; van Rooij PH; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1480-5. PubMed ID: 22285661
[TBL] [Abstract][Full Text] [Related]
17. Low-dose rate brachytherapy with I-125 seeds has an excellent 5-year outcome with few side effects in patients with low-risk prostate cancer.
Rasmusson E; Gunnlaugsson A; Kjellén E; Nilsson P; Einarsdottir M; Wieslander E; Fransson P; Ahlgen G; Blom R
Acta Oncol; 2016 Aug; 55(8):1016-21. PubMed ID: 27174603
[TBL] [Abstract][Full Text] [Related]
18. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer.
Burri RJ; Stone NN; Unger P; Stock RG
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1338-44. PubMed ID: 20138442
[TBL] [Abstract][Full Text] [Related]
20. Long-term potency preservation following brachytherapy for prostate cancer.
Snyder KM; Stock RG; Buckstein M; Stone NN
BJU Int; 2012 Jul; 110(2):221-5. PubMed ID: 22734475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]